Summary
University College London (UCL) is an educational institute that provides undergraduate, post-graduate, and life learning programs. It offers programs in the areas of arts and humanities, Bartlett faculty of the built environment, brain sciences, engineering, laws, life sciences, mathematical and physical sciences, medical sciences, population health sciences and social, and historical sciences. The university's services include alumini services, infrastructure management, finance and business affairs, human resource development, information services, library services, public and cultural engagement, and student and registry services. It carries out research in partnership with other research organisations, commerce and industry, and healthcare providers. UCL is headquartered in London, the UK.
University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University College London, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
University College London, Medical Devices Deals, 2010 to YTD 2016 12
University College London, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
University College London, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 17
Puridify Raises USD3.4 Million in Series A Financing 18
Puridify Raises USD1.43 Million in Seed Funding 19
Canbex Therapeutics Raises US$3 Million In Venture Financing 20
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 22
UCL Business Raises US$71 Million In First Round Financing 24
Partnerships 25
Cell Medica Enters into Partnership with University College London 25
Santen Pharma to Enter into Agreement with University College London 26
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 27
Teva Pharma Partners with University College London and Imanova 29
University College London Enters into Research Agreement with Takeda Pharma 30
Magnus Life Science Partners with University College London 31
UCL Business Forms Joint Venture with Syncona 32
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 33
Takeda Enters into R&D Agreement with University College London 35
iQur Enters into Co-Development Agreement with Six Consortium 36
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 38
Cellectis Enters Into Co-Development Agreement With University College London 39
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 40
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 41
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 42
TAP Biosystems Enters Into Co-Development Agreement With University College London 43
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 45
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 47
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 48
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 49
Eisai Enters Into Research Agreement With University College London 50
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 51
PolyTherics Enters Into Collaboration With University College London 53
AstraZeneca Enters Agreement With UCL Business To Develop Regenerative Medicines For Diabetic Retinopathy 54
AstraZeneca Enters Into Co-Development Agreement With University College London 56
Licensing Agreements 57
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 57
Achilles Therapeutics Enters into Licensing Agreement with University College London and Francis Crick Institute 58
Autolus Enters into Licensing Agreement with UCL Business 59
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 60
Oxford Pharmascience Extends Licensing Agreement With UCL Business 61
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 62
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 64
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 65
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 66
AbD Serotec Enters Into An Agreement With UCL Business 67
Asset Transactions 68
Freeline Therapeutics Acquires Intellectual Property Rights from UCL 68
University College London - Key Competitors 69
Key Employees 70
Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List of Tables
University College London, Pharmaceuticals & Healthcare, Key Facts 1
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University College London, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University College London, Deals By Therapy Area, 2010 to YTD 2016 10
University College London, Medical Devices Deals, 2010 to YTD 2016 12
University College London, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 17
Puridify Raises USD3.4 Million in Series A Financing 18
Puridify Raises USD1.43 Million in Seed Funding 19
Canbex Therapeutics Raises US$3 Million In Venture Financing 20
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 22
UCL Business Raises US$71 Million In First Round Financing 24
Cell Medica Enters into Partnership with University College London 25
Santen Pharma to Enter into Agreement with University College London 26
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 27
Teva Pharma Partners with University College London and Imanova 29
University College London Enters into Research Agreement with Takeda Pharma 30
Magnus Life Science Partners with University College London 31
UCL Business Forms Joint Venture with Syncona 32
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 33
Takeda Enters into R&D Agreement with University College London 35
iQur Enters into Co-Development Agreement with Six Consortium 36
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 38
Cellectis Enters Into Co-Development Agreement With University College London 39
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 40
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 41
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 42
TAP Biosystems Enters Into Co-Development Agreement With University College London 43
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 45
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 47
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 48
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 49
Eisai Enters Into Research Agreement With University College London 50
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 51
PolyTherics Enters Into Collaboration With University College London 53
AstraZeneca Enters Agreement With UCL Business To Develop Regenerative Medicines For Diabetic Retinopathy 54
AstraZeneca Enters Into Co-Development Agreement With University College London 56
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 57
Achilles Therapeutics Enters into Licensing Agreement with University College London and Francis Crick Institute 58
Autolus Enters into Licensing Agreement with UCL Business 59
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 60
Oxford Pharmascience Extends Licensing Agreement With UCL Business 61
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 62
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 64
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 65
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 66
AbD Serotec Enters Into An Agreement With UCL Business 67
Freeline Therapeutics Acquires Intellectual Property Rights from UCL 68
University College London, Key Competitors 69
University College London, Key Employees 70
University College London, Subsidiaries 71
List of Figures
University College London, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University College London, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
University College London, Medical Devices Deals, 2010 to YTD 2016 12
